Zhaorui Liu

Zhaorui Liu

Auto-generated profile, based on publicly available information

Zhaorui Liu

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
ZLZhaorui Liu
Zhaorui Liu
XWXuesong Wu
Xuesong Wu
SHSam T. Hwang
Sam T. Hwang
Jie LiuJie Liu
Jie Liu
Liu Z, et al. Ann Dermatol. 2021 Dec;33(6):487-496. https://doi.org/10.5021/ad.2021.33.6.487

1 January 2020 in Annals of Dermatology
Verified
Journal Article
Open access
YLYixin Luo
Yixin Luo
ZLZhaorui Liu
Zhaorui Liu
Jie LiuJie Liu
Jie Liu
YLYuehua Liu
Yuehua Liu
WZWei Zhang
Wei Zhang
YZYan Zhang
Yan Zhang
Mycosis fungoides (MF) is the most common types of cutaneous T cell lymphoma. It typically presents with erythematous patches and plaques in the early stage and tumors and extracutaneous involvement with possibly fatal outcomes in the late stage. To facilitate early and accurate diagnosis of MF, it is essential to be knowledgeable of classic and variants of this disease. However, there is limited published data in the Chinese population. To characterize our patient group and to provide additional insight into these malignancies. Patients diagnosed with mycosis fungoides and its variants from October 2012 to January 2018 were retrospectively analyzed. Disease-specific survival (DSS) rate and curve according to early and advanced stages were also calculated. The mean age at diagnosis of ninety-three MF patients was 38.9±1.73 years (range: 6~77). Forty-five males (48.4%) and 48 females (51.6 %) were included in this study. The DSS rate of early-stage MF was 98.6%, while that of advanced stage MF was 88.9%. There was a significant difference in DSS rate between early stage and advanced stage MF (p=00.042, log-rank test). The median age of 10 patients with hypopigmented MF (hMF) was 10.5 years (range: 6~28). The age of hMF was younger than that of classical MF patients (p<0.05). Early-stage MF has a better prognosis than advanced stage and hMF affects younger people than classic MF among Chinese. This study provides an insight into mycosis fungoides and its variants in a Chinese population.

23 December 2022 in Skin Research and Technology
Verified
Journal Article
Open access
ZLZhaorui Liu
Zhaorui Liu
ZNZihan Niu
Zihan Niu
DZDingding Zhang
Dingding Zhang
Jie LiuJie Liu
Jie Liu
QZQingli Zhu
Qingli Zhu
Background: Atopic dermatitis (AD) is a chronic inflammatory disease. Monoclonal antibody dupilumab was approved to treat moderate‐to‐severe AD in recent years. An objective assessment of treatment response by skin imaging modality is adjuvant for clinical evaluations. This study aimed to explore the value of dermoscopy and high‐frequency ultrasound (HFUS) imaging characteristics in treatment evaluation for moderate‐to‐severe AD patients treated with dupilumab.Methods: Moderate‐to‐severe AD patients refractory to conventional therapy were enrolled in the study. All patients went through at least a 16‐week standardized treatment of dupilumab. Clinical scores (eczema area scoring index [EASI], SCOARD, numerical rating scale of pruritus, dermatology life quality index), dermoscopy, and HFUS examinations were conducted at 0, 2, 4, 8, 12, and 16 weeks of treatment. Erythema, scales, erosion, and pigmentation under dermoscopy were scored, and subepidermal low‐echogenic band (SLEB) thickness under HFUS was measured as quantitative indexes. Descriptive analysis and mixed effect linear regression models were used for statistical analysis.Results: Sixteen patients were enrolled in the study and their average age was 45.63 ± 18.18 years. All clinical scores decreased with significant difference after 16‐week treatment compared with baseline. All patients achieved EASI 50 (EASI score decreased by 50% or more), and 9/16 patients reached EASI 75 after 16‐week treatment. Dermoscopy evaluation of erythema, scales and erosion scores were decreased, and the sign of pigmentation score was increased after treatment. For HFUS, the mean SLEB value was 0.51 ± 0.29 mm and decreased to 0.27 ± 0.15 mm after 16‐week treatment (p < 0.01). SLEB value decreased linearly with treatment time and correlated with clinical scores. However, SLEB values of two patients were 0.57 and 0.68 mm at week 16, respectively, which were higher than the average, and one of the patients showed EASI 75.Conclusion: Dermoscopy and HFUS were able to reveal deeper inflammation response than clinical scores in AD and can be an effective method to evaluate and monitor clinical improvement during dupilumab treatment for AD patients. The preliminary value of imaging methods for predicting the treatment endpoint of dupilumab remains to be verified.

1 January 2024 in Dermatologic Therapy
Verified
Journal Article
Open access
ZPZhiyu Pang
Zhiyu Pang
SZShan Zhang
Shan Zhang
ZLZhaorui Liu
Zhaorui Liu
WZWei Zhang
Wei Zhang
Jie LiuJie Liu
Jie Liu
Brentuximab vedotin (BV) has been approved for CD30‐positive cutaneous T‐cell lymphoma (CTCL) after at least one previous systemic treatment in China. However, real clinical practice is still limited. We aim to retrospectively review our experience with BV in a cohort of Chinese patients with CTCL, focusing on its efficacy and safety. We included 17 CTCL patients treated with BV at Peking Union Medical College Hospital from January 2021 to June 2024, including 12 with mycosis fungoides (MF)/Sézary syndrome (SS) and five with primary cutaneous anaplastic large‐cell lymphoma (pc‐ALCL). Patients had previously received a median of three treatment regimens (including acitretin, interferon, methotrexate, histone deacetylase inhibitors, phototherapy, radiotherapy, and chemotherapy). Sixteen patients received BV treatment at an initial dose of 1.8 mg/kg intravenously every 3 weeks, either as monotherapy (7/17) or in combination with gemcitabine, chidamide, or multiagent chemotherapy. The median treatment cycle has six cycles. Two patients received BV as the last treatment before undergoing allogeneic stem cell transplantation (alloSCT). The overall response rate (ORR) was 71% (13/17), with 18% (3/17) achieving complete remission (CR). In the MF/SS group, the ORR was 58% (7/12), while in the pc‐ALCL group, it was 100% (5/5). Adverse events (AEs) were observed in 12 patients, including peripheral neuropathy (PN) in three cases, fever in six cases, neutropenia in three cases, exfoliative dermatitis in two cases, and abnormal liver function in one case. Only one patient experienced ≥ Grade 3 AEs. Based on clinical experience in our center, BV, either as monotherapy or combined with chemotherapy, showed a good response in the treatment of advanced CTCL patients with good tolerability.

18 March 2026 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
ZLZhaorui Liu
Zhaorui Liu
HCHao Chen
Hao Chen
DZDingding Zhang
Dingding Zhang
YLYuehua Liu
Yuehua Liu
LWLei Wang
Lei Wang
HJHongzhong Jin
Hongzhong Jin